4 active not recruiting, 2 completed, 2 not yet recruiting, 2 unknown. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 3, Completed 2, Not yet recruiting 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow Lipoprotein Disorder: new trials by email Literature Review of Lipoprotein Disorder trials Research Report on Lipoprotein Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Oral HRS-5346 in Adult Patients With Elevated Lipoprotein(a) and High Risk of Cardiovascular Events HRS-5346 - Lipoprotein Disorder | Phase 2 | Not yet recruiting | Shandong Suncadia Medicine Co., Ltd. | 60 | 2026-09-01 | 2026-08-17 |
| Phase I Clinical Study Evaluating the Relative Bioavailability of Different Formulations of HRS-5346 in Healthy Participants HRS-5346 - Lipoprotein Disorder | Phase 1 | Not yet recruiting | Shandong Suncadia Medicine Co., Ltd. | 50 | 2026-08-01 | 2026-08-07 |
| A Study of DII235 in Adults With Elevated Lipoprotein(a) DII235, Saline - Lipoprotein Disorder | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 234 | 2025-12-02 | 2026-08-07 |
| Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a) Kylo-11 or matched placebo - Lipoprotein Disorder | Phase 2 | Active not recruiting | Kylonova (Xiamen) Biopharma co., LTD. | 204 | 2025-10-29 | 2026-10-16 |
| A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events HRS-5632 Injection, HRS-5632 Injection Placebo - Lipoprotein Disorder | Phase 2 | Active not recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 203 | 2025-10-21 | 2026-03-05 |
| The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Myocardial Deformation Lipoprotein Disorder, Arterial Stiffness | Recruiting | University of Athens | 300 | 2024-09-25 | 2026-03-11 | |
| A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events LY3473329, Placebo - Lipoprotein Disorder | Phase 2 | Completed | Eli Lilly and Company | 233 | 2022-11-24 | 2025-03-25 |
| A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)] LY3819469, Placebo - Lipoprotein Disorder | Phase 2 | Completed | Eli Lilly and Company | 320 | 2022-10-20 | 2025-05-28 |
| A Multi-center, Prospective, Observational Study to Describe the siTuation of Blood Lipid mAnagement Among the Population With hypeRtension and/or Type 2 diabeTes in Community Health Center Lipoprotein Disorder | Unknown | Huashan Hospital | 5000 | 2021-12-01 | 2021-10-18 | |
| Role of LipoprotEin(a) in CardiovascuLar Diseases and Premature Acute Coronary Syndromes - (RELACS) Study Acute Coronary Syndrome, Lipoprotein Disorder | Unknown | University of Campania Luigi Vanvitelli | 1000 | 2021-01-01 | 2022-08-11 | |
| Extreme Lipids Repository No intervention is involved in this study - Lipoprotein Disorder | Active not recruiting | University of Texas Southwestern Medical Center | 250 | 2019-05-10 | 2026-06-11 |
Cardiovascular Diseases (3) · Atherosclerosis (2) · Dyslipidemias (2) · Hyperlipidemias (2) · Acute Coronary Syndrome (1)
Vascular Diseases (3) · Arterial Occlusive Diseases (2) · Arteriosclerosis (2) · Lipid Metabolism Disorders (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Heart Diseases (1) · Myocardial Ischemia (1)
Sodium Chloride (1)
Eli Lilly and Company (2) · Shandong Suncadia Medicine Co., Ltd. (2) · Fujian Shengdi Pharmaceutical Co., Ltd. (1) · Huashan Hospital (1) · Kylonova (Xiamen) Biopharma co., LTD. (1) · Novartis Pharmaceuticals (1) · University of Athens (1) · University of Campania Luigi Vanvitelli (1) · University of Texas Southwestern Medical Center (1)
China (7) · United States (5) · Germany (3) · Japan (3) · Netherlands (2) · Argentina (1) · Australia (1) · Brazil (1) · Denmark (1) · Greece (1) · Hungary (1) · Italy (1) · Mexico (1) · Romania (1) · Spain (1)
Anand Rohatgi, MD (1) · Ignatios Ikonomidis (1)
PMID 38415744, PMID 17000623, PMID 18765436, PMID 21450600, PMID 29926099, PMID 32433854, PMID 32479194, PMID 36007992, PMID 36333256, PMID 38970537, PMID 39329200, PMID 39556768, PMID 40162643, PMID 40297899, PMID 42671367
K24HL146838 (1)